Nov 20 (Reuters) – Erasca said on Friday its experimental cancer pill shrank tumors in many patients with advanced pancreatic and lung cancers in an early-stage trial.
• Of 25 patients with pancreatic cancer taking a 32 mg daily dose of the drug, ERAS-0015, 44% saw tumors shrink significantly, Erasca said
• In patients with the two most common genetic variations of the disease, the response rate jumped to 69%
• In lung cancer, 60% of five patients who had already received immunotherapy and chemotherapy responded to the drug
• ERAS-0015 acts as a “molecular glue” that blocks faulty RAS proteins, effectively shutting down vital signals that cancer cells need to grow and multiply
• RAS proteins act as ‘on-off’ switches for cell growth, but can get stuck in the ‘on’ position when they mutate, driving uncontrolled growth of many common and deadly cancers
• Erasca said the treatment was generally well tolerated
• The company had earlier reported one death from lung inflammation in a patient taking a 24 mg dose of the drug
• Erasca plans to start late-stage clinical trials in both pancreatic and lung cancers in 2027
• The company said it would also test the drug alongside a second experimental treatment, ERAS-4001, starting in 2027
(Reporting by Kamal Choudhury in Bengaluru; Editing by Jonathan Ananda)

